Pharmaceutical Technology

FEBRUARY 18, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Hormones 100

Hormones Development Production Clinical Trials 100

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. billion in pharmaceutical sales from 2021.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

SEPTEMBER 14, 2020

US-based Merck, known as MSD outside North America, will globally develop and market Seattle’s investigational antibody-drug conjugate (ladiratuzumab vedotin). MSD will be responsible for ex-US filings including Europe and will record sales outside the US, Europe, and Canada. billion equity investment in 5.0

Genetics 52

Genetics Development Drugs Protein 52

pharmaphorum

OCTOBER 12, 2022

Gilead Sciences will hear back from the FDA in February next year about its marketing application for Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer, billed by the drugmaker as a key new indication for the drug.

HR 52

HR Sales Antibody Hormones 52

pharmaphorum

JULY 13, 2022

Meanwhile, Merck is also working with Seagen on the development of antibody-drug conjugate ladiratuzumab vedotin – both alone and in combination with Keytruda – for prostate cancer as well as other solid tumours. It is rumoured to be near to announcing a $40 billion takeover bid for the biotech.

Licensing 52

Licensing Licensing Hormones Production 52

pharmaphorum

AUGUST 8, 2022

It has the potential to be a sizeable new indication for Enhertu (trastuzumab deruxtecan), a HER2-targeting antibody-drug conjugate, and central to AZ and Daiichi Sankyo’s hopes of unlocking multibillion-dollar sales for the drug.

HR 52

HR Hormones Sales Antibody 52

XTalks

FEBRUARY 5, 2024

The top 40 best-selling oncology drugs in 2023, informed by 2022 sales statistics, mark significant milestones in cancer treatment and research. Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. Price of Revlimid: A supply of 28 oral 2.5 mg capsules is $24,576.

FDA Approval 52

FDA Approval Drugs Sales Development 52

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). Product Sales Performance. Key results include: Total revenues increased 5% to $6.5

Sales 52

Sales Production Antibody Development 52

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. It was also given FDA priority review. billion to $1.28

HR 98

HR FDA Approval Gene Trials 98

pharmaphorum

JANUARY 10, 2023

New drugs for immunological and inflammatory diseases feature prominently among new product launches this year that could top $1 billion in annual sales by 2027 or be clinical “game changers,” according to Clarivate.

Drugs 52

Drugs Gene Therapy Antibody Insulin 52

pharmaphorum

SEPTEMBER 9, 2022

Prospects for Gilead Sciences’ Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury is still out on what that might mean for the drug commercially.

HR 52

HR Hormones Trials Sales 52

XTalks

MARCH 22, 2021

The biotech acquisition deal includes Five Prime’s prime asset bemarituzumab, which is a first-in-class anti-FGFR2b antibody. The antibody accrued promising data in a randomized, placebo-controlled Phase II study in frontline advanced gastric or gastroesophageal junction (GEJ) cancer, and is now being prepared for Phase III trials.

Life Science 110

Life Science Development Marketing Gene Expression 110

pharmaphorum

AUGUST 16, 2022

The deal gives it worldwide ownership of Trodelvy (sacituzumab govitecan), a first-in-class TROP2 antibody-drug conjugate drug it acquired as part of its $21 billion takeover of Immunomedics in 2020.

Licensing 52

Licensing Licensing Hormones Drugs 52

pharmaphorum

JUNE 6, 2022

In Trodelvy’s favour is that the outlook for patients with HR+/HER2- breast cancer who have progressed despite earlier hormonal therapies, CDK4/6 inhibitors and multiple lines of chemo is pretty bleak. months of extra life, as well as improvements in quality of life measures including fatigue.

HR 52

HR Hormones Trials Drugs 52

Roots Analysis

SEPTEMBER 9, 2024

Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The rising demand for protein therapeutics, such as monoclonal antibodies and vaccines , is driving advancements in protein expression technology to ensure efficient and scalable production. Prokaryotic cells offer higher scalability and efficiency.

Protein 40

Protein Gene Production DNA 40

XTalks

MARCH 8, 2024

According to Amgen’s last earnings report , Prolia sales increased 12 percent last year to more than $4 billion, and Xgeva’s jumped five percent from last year to $2.1 Denosumab is a RANKL (receptor activator of nuclear factor kappa beta ligand) monoclonal antibody that blocks the ability of RANKL to bind to its receptor RANK.

Drugs 59

Drugs FDA Approval Production Immune Response 59

pharmaphorum

APRIL 28, 2022

When a company, a big pharma company, calculates the financial impact, they also consider the sales force that they need, the marketing. But the company was inspired to re-brand its rare disease business unit as a response to internal ramp-ups that have occurred over the last few years, Helfgott said. So that is the trick.

Pharma Companies 59

Pharma Companies Branding Development Marketing 59

The Pharma Data

AUGUST 6, 2020

As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive. billion in R&D and posted sales of CHF 61.5 receptors. In 2019, Roche invested CHF 11.7

Medicine 52

Medicine In-Vitro Protein Antibody 52

The Pharma Data

OCTOBER 26, 2020

Sales. Updated follow-up data from a Phase 1/2 study of quavonlimab (MK-1308), a novel investigational anti-CTLA-4 antibody, in combination with KEYTRUDA in patients with advanced NSCLC also was presented; a Phase 3 study of quavonlimab coformulated with KEYTRUDA in first-line advanced NSCLC is planned.

Sales 40

Sales Vaccination Vaccine Production 40

The Pharma Data

SEPTEMBER 16, 2020

Data will also be presented for two of our investigational hormone receptor (HR)-positive breast cancer treatments, both of which target the PI3K/AKT signalling pathway, a key driver of cancer cell growth and proliferation. billion in R&D and posted sales of CHF 61.5 GDC-0077 is our next generation investigational PI3K?

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

APRIL 27, 2021

As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive. billion in R&D and posted sales of CHF 58.3 receptors. In 2020, Roche invested CHF 12.2

Medicine 40

Medicine In-Vitro Antibody Development 40

The Pharma Data

SEPTEMBER 19, 2020

As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for all forms of early and advanced breast cancer, including triple-negative and hormone receptor-positive. billion in R&D and posted sales of CHF 61.5 receptors. In 2019, Roche invested CHF 11.7

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

MAY 4, 2021

Following the completion of the spin-off of the Upjohn Business (4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide. previously $59.4 previously 32.0% 21% to 22%.

Vaccination 40

Vaccination Vaccine Production Sales 40

XTalks

AUGUST 10, 2022

Enhertu is an antibody-drug conjugate (ADC) consisting of Roche’s Herceptin (trastuzumab), a monoclonal antibody against HER2 (human epidermal growth factor receptor 2), and the topoisomerase I inhibitor deruxtecan. The trial included 494 hormone receptor positive (HR+) patients and 63 hormone receptor negative (HR-) patients.

FDA Approval 98

FDA Approval HR Hormones Antibody 98

Pharmaceutical Technology

APRIL 24, 2023

. “Biologics products may contain proteins that control the action of other proteins and cellular processes, genes that control production of vital proteins, modified human hormones, or cells that produce substances that suppress or activate components of the immune system.

Contract Manufacturing 130

Contract Manufacturing Manufacturing Protein Sales 130

XTalks

NOVEMBER 26, 2024

The year 2023 was no exception, with several cancer drugs achieving remarkable sales milestones, reflecting their efficacy, expanding indications and the growing global cancer burden. In this blog, we highlight the top 10 cancer drugs to watch in 2024, based on their impressive 2023 sales figures and anticipated market dynamics.

Sales 105

Sales FDA Approval Drugs Marketing 105

XTalks

DECEMBER 6, 2024

While both semaglutide and tirzepatide have a glucagon-like peptide-1 (GLP-1) agonist component, tirzepatide also acts as an agonist of the gastric inhibitory polypeptide (GIP) hormone; this serves as a differentiator between the two and could explain tirzepatides stronger weight loss effects.

Trials 98

Trials Clinical Trials Clinical Trials Marketing 98